TRPV4 and autosomal recessive polycystic kidney disease: In contrast, impaired TRPV4 activity in cystic cells either due to pharmacological antagonism with GSK2193874 or as a result of treatment with high KB/C diet favors the cAMP‐dependent phenotype thus greatly accelerating ARPKD progression and renal injury (Figure 8, left panel).